{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T15:20:44Z","timestamp":1795101644218,"version":"4.10.3"},"reference-count":49,"publisher":"American Society of Hematology","issue":"22","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,30]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, targets antithrombin to rebalance hemostasis in people with hemophilia A or B (PwHA\/B), irrespective of inhibitor status. This phase 3, open-label study evaluated the efficacy and safety of fitusiran prophylaxis in males aged \u226512 years with hemophilia A or B, with or without inhibitors, who received prior bypassing agent (BPA)\/clotting factor concentrate (CFC) prophylaxis. Participants continued their prior BPA\/CFC prophylaxis for 6 months before switching to once-monthly 80 mg fitusiran prophylaxis for 7 months (onset and efficacy periods). Primary end point was annualized bleeding rate (ABR) in the BPA\/CFC prophylaxis and fitusiran efficacy period. Secondary end points included spontaneous ABR (AsBR) and joint ABR (AjBR). Safety and tolerability were assessed. Of 80 enrolled participants, 65 (inhibitor, n\u00a0= 19; noninhibitor, n\u00a0= 46) were eligible for ABR analyses. Observed median ABRs were 6.5 (interquartile range [IQR], 2.2-19.6)\/4.4 (IQR, 2.2-8.7) with BPA\/CFC prophylaxis vs 0.0 (IQR, 0.0-0.0)\/0.0 (IQR, 0.0-2.7) in the corresponding fitusiran efficacy period. Estimated mean ABRs were substantially reduced with fitusiran by 79.7% (P\u00a0= .0021) and 46.4% (P\u00a0= .0598) vs BPA\/CFC prophylaxis, respectively. Forty-one participants (63.1%) experienced 0 treated bleeds with fitusiran vs 11 (16.9%) with BPAs\/CFCs. Median AsBR and AjBR were both 2.2 with BPA\/CFC prophylaxis and 0.0 in the fitusiran efficacy period. Two participants (3.0%) experienced suspected or confirmed thromboembolic events with fitusiran. Once-monthly fitusiran prophylaxis significantly reduced bleeding events vs BPA\/CFC prophylaxis in PwHA\/B, with or without inhibitors, and reported adverse events were generally consistent with previously identified risks of fitusiran. This trial was registered at www.ClinicalTrials.gov as #NCT03549871.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023021864","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T14:57:31Z","timestamp":1709823451000},"page":"2256-2269","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":57,"title":["Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA\/CFC prophylaxis: the ATLAS-PPX trial"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3494-9823","authenticated-orcid":false,"given":"Gili","family":"Kenet","sequence":"first","affiliation":[{"name":"1The National Hemophilia Centre, Amalia Biron Thrombosis Research Institute, Sheba Medical Centre, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0145-4736","authenticated-orcid":false,"given":"Beatrice","family":"Nolan","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Children's Health Ireland at Crumlin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7586-6939","authenticated-orcid":false,"given":"Bulent","family":"Zulfikar","sequence":"additional","affiliation":[{"name":"3Division of Pediatric Hematology-Oncology, Istanbul University Oncology Institute, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6058-6021","authenticated-orcid":false,"given":"Bulent","family":"Antmen","sequence":"additional","affiliation":[{"name":"4Department of Pediatric Hematology\/Oncology and Bone Marrow Transplantation Unit, Faculty of Medicine, Acibadem University, Adana Hospital, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kampmann","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3646-3125","authenticated-orcid":false,"given":"Tadashi","family":"Matsushita","sequence":"additional","affiliation":[{"name":"6Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chur-Woo","family":"You","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, Daejeon Eulji Medical Center, Eulji University School of Medicine, Daejeon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Vilchevska","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Ohmatdyt National Children\u2019s Specialized Hospital, Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-9706","authenticated-orcid":false,"given":"Catherine N.","family":"Bagot","sequence":"additional","affiliation":[{"name":"9Department of Haematology, Glasgow Royal Infirmary, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azizan","family":"Sharif","sequence":"additional","affiliation":[{"name":"10Hospital Sultanah Aminah, Johor Bahru, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[{"name":"11Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"},{"name":"12Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6013-1254","authenticated-orcid":false,"given":"Guy","family":"Young","sequence":"additional","affiliation":[{"name":"13Hemostasis and Thrombosis Center, Cancer and Blood Diseases Institute, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2905-055X","authenticated-orcid":false,"given":"Claude","family":"Negrier","sequence":"additional","affiliation":[{"name":"14UR4609 Hemostasis and Thrombosis, Claude Bernard University Lyon 1, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Chi","sequence":"additional","affiliation":[{"name":"15Sanofi, Bridgewater, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kittner","sequence":"additional","affiliation":[{"name":"15Sanofi, Bridgewater, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sussebach","sequence":"additional","affiliation":[{"name":"16Sanofi, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Shammas","sequence":"additional","affiliation":[{"name":"17Sanofi, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baisong","family":"Mei","sequence":"additional","affiliation":[{"name":"18Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna","family":"Andersson","sequence":"additional","affiliation":[{"name":"18Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4910-2142","authenticated-orcid":false,"given":"Kaan","family":"Kavakli","sequence":"additional","affiliation":[{"name":"19Department of Haematology, Ege University Faculty of Medicine, Children's Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2024053015204653400_bib1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-07-820712","article-title":"New therapies using nonfactor products for patients with hemophilia and inhibitors","volume":"133","author":"Nogami","year":"2019","journal-title":"Blood"},{"key":"2024053015204653400_bib2","doi-asserted-by":"crossref","first-page":"100582","DOI":"10.1016\/j.blre.2019.05.006","article-title":"The\u00a0central role of thrombin in bleeding disorders","volume":"38","author":"Negrier","year":"2019","journal-title":"Blood Rev"},{"issue":"suppl 6","key":"2024053015204653400_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"7528","key":"2024053015204653400_bib4","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1038\/515S168a","article-title":"Thrombosis: balancing act","volume":"515","author":"Willyard","year":"2014","journal-title":"Nature"},{"issue":"3","key":"2024053015204653400_bib5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3324\/haematol.2019.232132","article-title":"Hemophilia therapy: the future has begun","volume":"105","author":"Mannucci","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2024053015204653400_bib6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/hae.14697","article-title":"Life-threatening complication of central venous catheter in a child with severe haemophilia A","volume":"29","author":"Tomaszewska","year":"2023","journal-title":"Haemophilia"},{"issue":"suppl 6","key":"2024053015204653400_bib7","first-page":"S112","article-title":"Current challenges in the management of hemophilia","volume":"21","author":"Bauer","year":"2015","journal-title":"Am J Manag\u00a0Care"},{"issue":"1","key":"2024053015204653400_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2019.239160","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study","volume":"106","author":"Male","year":"2021","journal-title":"Haematologica"},{"key":"2024053015204653400_bib9","doi-asserted-by":"crossref","first-page":"100852","DOI":"10.1016\/j.blre.2021.100852","article-title":"Optimising prophylaxis in haemophilia A: the ups and downs of treatment","volume":"50","author":"Berntorp","year":"2021","journal-title":"Blood Rev"},{"issue":"13","key":"2024053015204653400_bib10","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"Oldenburg","year":"2015","journal-title":"Blood"},{"key":"2024053015204653400_bib11","author":"Carcao","year":"2018.   2024","edition":"5th ed."},{"issue":"3","key":"2024053015204653400_bib12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4155\/cli.14.122","article-title":"Immune tolerance induction in hemophilia","volume":"5","author":"Mancuso","year":"2015","journal-title":"Clin Invest"},{"issue":"2","key":"2024053015204653400_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/hae.13655","article-title":"Bleeding and safety outcomes in persons with haemophilia A without inhibitors: results from a prospective non-interventional study in a real-world setting","volume":"25","author":"Kruse-Jarres","year":"2019","journal-title":"Haemophilia"},{"issue":"11","key":"2024053015204653400_bib14","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","article-title":"Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the joint outcome continuation study","volume":"4","author":"Warren","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2024053015204653400_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/hae.14171","article-title":"Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis","volume":"27","author":"O'Hara","year":"2021","journal-title":"Haemophilia"},{"issue":"suppl 5","key":"2024053015204653400_bib16","first-page":"s126","article-title":"Economic costs of hemophilia and the impact of prophylactic treatment on patient management","volume":"22","author":"Chen","year":"2016","journal-title":"Am J Manag Care"},{"issue":"21","key":"2024053015204653400_bib17","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2017-08-742312","article-title":"Novel approaches to hemophilia therapy: successes and challenges","volume":"130","author":"Arruda","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2024053015204653400_bib18","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2024053015204653400_bib19","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2024053015204653400_bib20","first-page":"2194","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"2024053015204653400_bib21","doi-asserted-by":"crossref","first-page":"20406207221085202","DOI":"10.1177\/20406207221085202","article-title":"International consensus recommendations on the management of people with haemophilia B","volume":"13","author":"Hart","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"19","key":"2024053015204653400_bib22","first-page":"4303","article-title":"Real-world data on bleeding patterns of hemophilia A patients treated with emicizumab","volume":"10","author":"Levy-Mendelovich","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"9","key":"2024053015204653400_bib23","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1111\/jth.14957","article-title":"Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: new case with detailed laboratory evaluation","volume":"18","author":"Harkins Druzgal","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"12","key":"2024053015204653400_bib24","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1111\/jth.15506","article-title":"Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A","volume":"19","author":"Kaneda","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2024053015204653400_bib25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/hae.14757","article-title":"Pain while injecting emicizumab predominant in children, a report of Dutch patient experiences","volume":"29","author":"Kruis","year":"2023","journal-title":"Haemophilia"},{"issue":"5","key":"2024053015204653400_bib26","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"issue":"9","key":"2024053015204653400_bib27","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"2024053015204653400_bib28","first-page":"135","article-title":"An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B","volume":"9","author":"Machin","year":"2018","journal-title":"J\u00a0Blood Med"},{"issue":"5","key":"2024053015204653400_bib29","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"issue":"10386","key":"2024053015204653400_bib30","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"2024053015204653400_bib31","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Subcommittee on factor VIII, factor IX and rare coagulation disorders of\u00a0the scientific and standardization committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2024053015204653400_bib32","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/hae.12642","article-title":"Interpreting important health-related quality of life change using the Haem-A-QoL","volume":"21","author":"Wyrwich","year":"2015","journal-title":"Haemophilia"},{"issue":"1","key":"2024053015204653400_bib33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","article-title":"Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury","volume":"147","author":"Robles-Diaz","year":"2014","journal-title":"Gastroenterology"},{"issue":"6","key":"2024053015204653400_bib34","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jth.15270","article-title":"Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-results of the phase 1 inhibitor cohort","volume":"19","author":"Pasi","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"suppl 1","key":"2024053015204653400_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-136501","article-title":"Long-term durability, safety and efficacy of fitusiran prophylaxis in people with hemophilia A or B, with or without inhibitors - results from the phase II study [abstract]","volume":"136","author":"Pipe","year":"2020","journal-title":"Blood"},{"key":"2024053015204653400_bib36","first-page":"209","article-title":"Asymptomatic joint bleeding and joint health in hemophilia: a review of variables, methods, and biomarkers","volume":"12","author":"Gooding","year":"2021","journal-title":"J\u00a0Blood Med"},{"key":"2024053015204653400_bib37","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2147\/PPA.S87659","article-title":"Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study","volume":"9","author":"Forsyth","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"2024053015204653400_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.17225\/jhp00061","article-title":"Pain: the voiceless scream in every haemophilia patient\u2019s life","volume":"3","author":"Rambod","year":"2016","journal-title":"J\u00a0Haemophilia Pract"},{"issue":"1","key":"2024053015204653400_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/hae.13862","article-title":"Achieving the unimaginable: health equity in\u00a0haemophilia","volume":"26","author":"Skinner","year":"2020","journal-title":"Haemophilia"},{"issue":"6","key":"2024053015204653400_bib40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2024053015204653400_bib41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A\u00a0review of patisiran (ONPATTRO\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol Ther"},{"key":"2024053015204653400_bib42","author":"Negrier","year":"2021"},{"issue":"12","key":"2024053015204653400_bib43","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/jth.14296","article-title":"The future of bypassing agents for hemophilia with inhibitors in the era of novel agents","volume":"16","author":"Shapiro","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"suppl\u00a01","key":"2024053015204653400_bib44","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1182\/blood-2021-146147","article-title":"Evaluation of the safety of emicizumab prophylaxis in persons with hemophilia A: an updated summary of thrombotic events and thrombotic microangiopathies [abstract]","volume":"138","author":"Howard","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2024053015204653400_bib45","first-page":"298","article-title":"Thrombotic complications in patients with hereditary bleeding disorders","volume":"92","author":"Franchini","year":"2004","journal-title":"Thromb Haemost"},{"issue":"3","key":"2024053015204653400_bib46","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/j.1365-2516.2012.02758.x","article-title":"Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies","volume":"18","author":"Coppola","year":"2012","journal-title":"Haemophilia"},{"issue":"3","key":"2024053015204653400_bib47","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jtha.2023.01.010","article-title":"Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021","volume":"21","author":"Abbattista","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"2024053015204653400_bib48","article-title":"Fitusiran, an investigational siRNA therapeutic targeting antithrombin: analysis of antithrombin levels and thrombin generation from a phase 3 study in people with haemophilia A or B without inhibitors [abstract]","volume":"7","author":"Pipe","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"2024053015204653400_bib49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1160\/TH04-10-0706","article-title":"Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B","volume":"93","author":"Dargaud","year":"2005","journal-title":"Thromb Haemost"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/22\/2256\/2226700\/blood_bld-2023-021864-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/22\/2256\/2226700\/blood_bld-2023-021864-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T11:21:29Z","timestamp":1717068089000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/22\/2256\/515220\/Fitusiran-prophylaxis-in-people-with-hemophilia-A"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":49,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,5,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021864","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}